• Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC
  • DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States
  • LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB
  • LevelJump Healthcare is a national medical diagnostic imaging company providing radiology support to hospitals, emergency rooms and private clinics
  • LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET

Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC. 

DTC is a subsidiary of the Depository Trust & Clearing Corp. (DTCC) that manages the electronic clearing and settlement of publicly-traded companies in the United States.

LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB.

Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States.

Mitch Geisler, CEO commented on the benefits of DTC eligibility.

“With DTC eligibility, our shares will be more accessible to a broader range of investors in the U.S. This should allow LevelJump to increase its global shareholder base and increase the liquidity of our common shares to the benefit of all investors.” 

LevelJump Healthcare is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers.

LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.